FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Limits Population

FDA has lifted the clinical hold on development of Dynavax's Hepatitis B vaccine Heplisav, allowing the firm to proceed with Phase III development - but in a smaller market than originally proposed: patients with chronic kidney disease